The emergence of drugs like copyright and Semaglutide signifies a remarkable shift in how we manage type 2 diabetes. These innovative therapies belong to a class known as GLP-1 target agonists, which mimic the effects of a natural hormone that manages glucose levels and appetite. First, developed for diabetes, their effectiveness in facilitating fa